QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:GMDA

Gamida Cell Stock Forecast, Price & News

$8.15
-0.15 (-1.81 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.10
Now: $8.15
$8.87
50-Day Range
$7.83
MA: $9.68
$12.43
52-Week Range
$2.60
Now: $8.15
$15.00
Volume658,382 shs
Average Volume1.26 million shs
Market Capitalization$197.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Gamida Cell logo

Headlines

2 Top Biotech Stocks to Buy in February
February 17, 2021 |  finance.yahoo.com
Gamida Cell Added to NASDAQ Biotechnology Index
December 18, 2020 |  finance.yahoo.com
Is GMDA A Good Stock To Buy Now?
December 10, 2020 |  finance.yahoo.com
Why Is Everyone Talking About Gamida Cell Stock?
December 10, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GMDA
CUSIPN/A
CIKN/A
Phone972-2659-5666
Employees79
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.44 per share

Profitability

Net Income$-34,350,000.00

Miscellaneous

Market Cap$197.39 million
Next Earnings Date3/9/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

667th out of 1,971 stocks

Biological Products, Except Diagnostic Industry

90th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$8.15
-0.15 (-1.81 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for GMDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gamida Cell (NASDAQ:GMDA) Frequently Asked Questions

Is Gamida Cell a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Gamida Cell stock.
View analyst ratings for Gamida Cell
or view top-rated stocks.

What stocks does MarketBeat like better than Gamida Cell?

Wall Street analysts have given Gamida Cell a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gamida Cell wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Gamida Cell?

Gamida Cell saw a increase in short interest during the month of February. As of February 12th, there was short interest totaling 1,330,000 shares, an increase of 83.5% from the January 28th total of 724,800 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 1.1 days.
View Gamida Cell's Short Interest
.

When is Gamida Cell's next earnings date?

Gamida Cell is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Gamida Cell
.

How can I listen to Gamida Cell's earnings call?

Gamida Cell will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) issued its quarterly earnings results on Sunday, November, 15th. The company reported ($0.30) EPS for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.01.
View Gamida Cell's earnings history
.

How has Gamida Cell's stock been impacted by Coronavirus (COVID-19)?

Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GMDA stock has increased by 92.7% and is now trading at $8.15.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for GMDA?

5 Wall Street analysts have issued 1-year price objectives for Gamida Cell's stock. Their forecasts range from $13.00 to $27.00. On average, they expect Gamida Cell's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 127.0% from the stock's current price.
View analysts' price targets for Gamida Cell
or view top-rated stocks among Wall Street analysts.

Who are Gamida Cell's key executives?

Gamida Cell's management team includes the following people:
  • Dr. Julian Adams Ph.D., CEO & Director (Age 66, Pay $740k)
  • Mr. Shai Lankry CPA, M.B.A., Chief Financial Officer (Age 45, Pay $353k)
  • Dr. Ronit Simantov, Chief Medical Officer (Age 56, Pay $587k)
  • Mr. Joshua D. Hamermesh MBA, Chief Bus. Officer (Age 49, Pay $508k)
  • Ms. Michele Ilene Korfin M.B.A., R.Ph., Chief Operating & Chief Commercial Officer (Age 49)
  • Dr. Tracey Lodie Ph.D., Chief Scientific Officer (Age 51)
  • Mr. Paul Nee, VP of Marketing
  • Mr. Matthew Metivier, VP of Human Resource
  • Mr. Naftali Brikashvili CPA, Sr. VP Fin. & Operations
  • Mr. Tzvi Palash, Chief Manufacturing Officer (Age 64)

Who are some of Gamida Cell's key competitors?

What other stocks do shareholders of Gamida Cell own?

When did Gamida Cell IPO?

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Who are Gamida Cell's major shareholders?

Gamida Cell's stock is owned by a number of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (20.86%), Baker BROS. Advisors LP (6.39%), BlackRock Inc. (1.81%), Stonepine Capital Management LLC (1.57%), Ikarian Capital LLC (0.66%) and Victory Capital Management Inc. (0.53%).

Which institutional investors are selling Gamida Cell stock?

GMDA stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Phoenix Holdings Ltd., Squarepoint Ops LLC, and Victory Capital Management Inc..

Which institutional investors are buying Gamida Cell stock?

GMDA stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Baker BROS. Advisors LP, BlackRock Inc., Stonepine Capital Management LLC, Ikarian Capital LLC, Silverarc Capital Management LLC, Virtus ETF Advisers LLC, and Barclays PLC.

How do I buy shares of Gamida Cell?

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $8.15.

How much money does Gamida Cell make?

Gamida Cell has a market capitalization of $197.39 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Gamida Cell have?

Gamida Cell employs 79 workers across the globe.

What is Gamida Cell's official website?

The official website for Gamida Cell is www.gamida-cell.com.

Where are Gamida Cell's headquarters?

Gamida Cell is headquartered at 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.